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Abstract
Introduction: miRNAs are very important regulators in biological processes such as development, cellular
differentiation, and carcinogenesis. Given the important role of miRNAs in tumorigenesis and development, it is
worth investigating whether some miRNAs play roles in the anticancer mechanism of flavonoids. However, such a
role has not yet been reported. We previously selected the promising anticancer agent 3,6-dihydroxyflavone (3,6-
DHF) in pharmacodynamic experiments, which may serve as a leading compound for developing more potent
anticancer drugs or chemopreventive supplements. The present study aims to investigate the chemopreventive
activities of 3,6-DHF against mammary carcinogenesis.
Methods: The experimental model of breast carcinogenesis was developed by intraperitoneal injection of 1-
methyl-1-nitrosourea (MNU). The bioavailability of 3,6-DHF in rats was detected by HPLC. The expression of
microRNA-34a (miR-34a) and microRNA-21 (miR-21) was evaluated by real-time quantitative RT-PCR. Cell apoptosis
was analyzed by flow cytometry or terminal deoxynucleotidyl transferase dUTP nick end-labeling assay. The
mitochondrial membrane potential was assayed using 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethyl-imidacarbocyanine
iodide dye by confocal laser scanning microscopy. The level of cytochrome C in cytosol was evaluated by western
blotting.
Results: Our study showed that oral administration of 3,6-DHF effectively suppressed MNU-induced breast
carcinogenesis in rats, decreasing the cancer incidence by 35.7%. The detection of bioavailability indicated that the
concentration of 3,6-DHF was 2.5 ± 0.4 μg/ml in plasma of rats within 2 hours after administration, and was 21.7 ±
3.8 μg/ml in urine within 24 hours. Oral administration of 3,6-DHF to BALB/c nude mice bearing breast cancer cell
xenografts also significantly suppressed tumor growth in vivo. Furthermore, our study revealed that the global
upregulation of miR-21 and downregulation of miR-34a in breast carcinogenesis could be reversed by 3,6-DHF,
which significantly upregulated miR-34a expression and decreased miR-21 expression - inducing apoptosis of
breast cancer cells in vitro and in vivo. Overexpression of miR-34a induced by plasmid transfection or inhibition of
miR-21 by oligonucleotides markedly promoted the pro-apoptotic effect of 3,6-DHF. Inactivation of miR-34a or
overproduction of miR-21 compromised the anticancer effects of 3,6-DHF.
Conclusion: These findings indicate that 3,6-DHF is a potent natural chemopreventive agent, and that miR-34a
and miR-21 play roles in MNU-induced breast carcinogenesis and the anticancer mechanism of flavonoids.
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Introduction
Breast cancer is the leading cause of cancer death in
women worldwide due to the complicated etiology invol-
ving both genetic and environmental factors. About
70,000 new cases of breast cancer are likely to be diag-
nosed annually. Understanding the signaling pathways
involved in breast carcinogenesis is important for the
development of more effective tumor prevention and
therapies. miRNAs are a class of noncoding RNAs 18 to
25 nucleotides long that negatively regulate gene expres-
sion by binding to the 3’-UTR of target messenger
mRNAs, causing translational repression or degradation.
Deregulation of miRNAs has been demonstrated to play
roles in the pathogenesis of human diseases, including
malignancy [1,2]. Some miRNAs have been identified
from cancers and appear to play crucial roles in prolifera-
tion, differentiation, and apoptosis [3-5]. One of these,
microRNA-21 (miR-21), is a key player. As an anti-apop-
tosis factor, aberrantly expressed miR-21 compromises
tumor suppressor-mediated apoptosis of cancer cells
[6,7]. However, more studies are needed to define the
functional role of miR-21 in breast tumorigenesis.
p53 is a potent tumor suppressor. Activated p53 elicits
a plethora of biochemical and biological outcomes, ran-
ging from repair of minor damage to cessation of cell-
cycle progression, induction of replicative senescence,
and apoptosis. The p53 inactivation is one of the most
frequent genetic alterations in human cancer [8,9]. Stu-
dies have reported that, in addition to regulating the
expression of hundreds of protein-coding genes, p53
also modulates the levels of miRNAs. Among those p53-
related miRNAs, microRNA-34a (miR-34a) is a typical
one. As a pro-apoptotic transcriptional target of p53,
miR-34a exerts anti-proliferative effects and contributes
to p53-mediated apoptosis [10,11]. Monitoring miR-34a
expression in human tumors and manipulating its levels
may provide new clues for cancer prevention, diagnosis,
and therapy. Given the importance of pro-apoptosis
activity of miR-34a and anti-apoptosis activity of miR-21
in cancer cells, it is interesting to investigate their roles
in carcinogenesis. We hypothesize that the disbalance of
cell apoptosis signaling regulation plays an important
role in breast tumorigenesis.
Flavonoids, a class of natural polyphenolic compounds,
are widely found in abundance in fruits, vegetables, and
other vegetable diets. Epidemiological investigation and
experimental studies have confirmed that plant flavo-
noids have extensive biological benefits such as antioxi-
dant, anti-inflammatory, anti-tumor, and anti-
atherosclerotic properties [12-15]. Recent recognition of
the fact that a diet rich in plant foods lowers the risks of
cancer arouses interest in isolating and characterizing the
nutritive and non-nutritive components in fruits,
vegetables, and cereals for potential chemopreventive and
pharmaceutical agents. Development of anticancer agents
from flavonoids and other natural products has currently
become a very hot topic. Our preliminary screening of
anticancer drugs from 23 flavonoid compounds identified
3,6-dihydroxyflavone (3,6-DHF) as a promising antican-
cer agent with a very strong cytotoxicity against breast
cancer cells, which may serve as a leading compound for
developing more potent anticancer drugs or chemopre-
ventive supplements [16,17]. However, whether 3,6-DHF
possesses effective anticancer properties in vivo and its
chemopreventive activities against mammary carcinogen-
esis remain unclear. Furthermore, given the important
role of miRNAs in tumorigenesis and development, it is
worth investigating whether some miRNAs play roles in
the anticancer mechanism of flavonoids. However, such a
role has not yet been reported.
In this study, we evaluated the chemopreventive effect
of 3,6-DHF on mammary carcinogenesis, and investi-




Female Sprague-Dawley rats (age 42 to 48 days, weight
145 to 165 g) and BALB/c nude mice (age 42 to 48
days, weight 15 to 20 g) were obtained from the Medical
Experimental Animal Center of the Third Military Med-
ical University (SCXK-(army)-2007-015). The rats were
bred and maintained in accordance with our institu-
tional guidelines for the use of laboratory animals. Ani-
mal rooms were maintained at 25°C with 50% relative
humidity and a 12-hour light/12-hour dark cycle. All
animal procedures were approved by the Animal Ethics
Committee of the Third Military Medical University.
Cell lines
Human breast cancer cell lines MDA-MB-453 and
MDA-MB-231 were purchased from the Institute of
Biochemistry and Cell Biology, Chinese Academy of
Sciences (Shanghai, China). MDA-MB-453 cells were
grown in RPMI 1640 medium and MDA-MB-231 cells
were grown in DMEM/F12 medium supplemented with
10% fetal bovine serum in a humidified atmosphere of
5% CO2/95% air at 37°C. The human vascular endothe-
lial cell line EA.hy926 was grown in DMEM medium
supplemented with 100 U/ml penicillin, 100 μg/ml
streptomycin and 10% fetal bovine serum at 37°C under
a humidified atmosphere with 5% CO2/95% air.
Chemicals and reagents
Growth media supplemented with 2 mM glutamine and
fetal bovine serum were purchased from Hyclone
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(Beijing, China). The Annexin V-FITC Vybrant Apopto-
sis Assay Kit and the 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetra-
ethyl-imidacarbocyanine iodide (JC-1) dye were
purchased from Molecular Probes Inc. (Eugene, OR,
USA). Antibodies of cytochrome C were purchased
from Cell Signaling Technology Inc. (Danvers, MA,
USA). The in situ cell death detection kit (terminal
deoxynucleotidyl transferase-mediated dUTP nick end-
labeling (TUNEL)) was purchased from Roche Diagnos-
tics (Mannheim, Germany). Trizol reagent, lipofecta-
mine 2000 and Opti-Mem were purchased from
Invitrogen (Carlsbad, CA, USA). 3,6-DHF, 1-methyl-1-
nitrosourea (MNU), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT), dimethylsulfoxide,
PBS and other chemicals were purchased from Sigma-
Aldrich (St. Louis, MO, USA).
Experimental model of carcinogenesis
The rats were acclimatized on an AIN-93G diet for 3
days and randomly divided into four groups: normal,
control, low-dosage treatment and high-dosage treat-
ment groups. Rats in the low-dosage and the high-
dosage treatment groups were fed intragastrically with
10 and 20 mg/kg/day 3,6-DHF, respectively; rats in the
normal and the control groups were fed orally (intragas-
trically) with vehicle alone (normal saline). One week
later, except for the normal group, all rats were given a
single intraperitoneal injection of MNU (50 mg/kg body
weight) that was dissolved in physiological saline (10
mg/ml) containing 0.05% acetic acid and used within 30
minutes after preparation. Rats in the normal group
were injected with an equal volume of physiological sal-
ine. During the experiments, the rats were weighed
twice per week and palpated once per day. The rats
were monitored for mammary tumor development
throughout the study and at sacrifice. The following
parameters were calculated: tumor latency, the average
time of tumor appearance; tumor incidence, the percen-
tage of rats bearing at least one palpable malignant
mammary tumor; tumor multiplicity, the total number
of malignant mammary tumors in each group; and
tumor volume and weight, the average volume and
weight of all malignant tumors in each experimental
group.
Detection of miR-34a and miR-21 expression in breast
tumors
A total of 30 rats were randomly divided into control
and treatment groups. Animals were treated in the way
described above for experimental models of tumorigen-
esis. Rats in the treatment group were fed with 20 mg/
kg/day 3,6-DHF. After MNU injection for 0, 4, 8 and 18
weeks, three rats in each group were randomly selected
out respectively and were sacrificed. Breast tissue (at 0,
4 and 8 weeks) and tumors (at 18 weeks) were clipped
for total RNA extraction. The expression of miR-34a
and miR-21 was detected by quantitative RT-PCR as
mentioned below.
HPLC analysis of 3,6-dihydroxyflavone
The urine sample or plasma sample (1.0 ml) was added
with 5 μl b-glucuronidase (≥2,000 units/ml), 5 μl sulfa-
tase (≥8,500 units/ml) and 1.5 ml sodium acetate solu-
tion (0.2 M), and then incubated in water for 30
minutes at 37°C. The mixed solution was added with 5.0
ml ethyl acetate (0.2 M), and centrifuged (3,000 rpm) for
10 minutes at 4°C. The supernatant solution was dried
under reduced pressure for 5 hours at 40°C. The residue
was dissolved with methanol and treated with 0.45 μm
membrane filtration, and then analyzed by HPLC. HPLC
analyses were carried out on a Waters 1525 series liquid
chromatography system equipped with a dual l absor-
bance detector (Waters, Milford, MA, USA). The ana-
lyses were performed with a Hyper 0DS2 C18 column
(4.6 mm × 50 mm, 1.8 μm; Waters, Milford, MA, USA)
with 0.5% ethanoic acid or methanol as the mobile
phase. Elution started at 15% (methanol), increasing to
67% within 40 minutes at a flow rate of 1.0 ml/minute.
3,6-DHF was quantified based on the peak area of the
respective standard curves measured at 270 nm. Typi-
cally, 20 μl was injected for the analyses.
Anti-tumor effect of 3,6-dihydroxyflavone on xenografted
MDA-MB-453 cells in athymic mice
Female immunodeficient BALB/c nude mice were ran-
domized and then implanted with MDA-MB-453 cells
at a density of 2 × 106 cells/ml subcutaneously into the
right axilla. Mice were fed orally (intragastrically) 72
hours later with 3,6-DHF (10 or 20 mg/kg/day; n = 6)
or vehicle alone (normal saline; n = 6). Tumor size was
measured once every 4 days in two perpendicular
dimensions with vernier calipers and converted to
tumor volume (Vt) using the formula: (L×W
2)/2, where
L and W refer to the longer and shorter dimensions,
respectively.
The results are expressed as the ratio of median
tumor volumes of treated animals and of control ani-
mals (T/C):
T/C (%) = median Vt of treated animals / median Vt of control animals× 100
Cell viability assay
Cell viability was assessed by MTT assay as described
previously [18]. Cells in the logarithmic growth phase
were plated in 24-well plates at a density of 105 cells/
well. At the end of the treatment, 40 μl MTT (5 mg/ml)
were added to each well and the cells were cultured for
another 4 hours. The formazan crystals were dissolved
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in dimethylsulfoxide, and the absorbance of each well
was measured at 490 nm on a Bio-Rad automatic EIA
analyzer (Bio-Rad, Hercules, CA, USA).
Detection of apoptosis by flow cytometry
Treated cells were washed three times with ice-cold
PBS, and stained with Annexin V-FITC for 15 minutes
at room temperature in 200 μl binding buffer. An addi-
tional 300 μl binding buffer was then added. The cells
were stained with propidium iodide for 30 minutes at 4°
C and the fluorescence intensity was determined by flow
cytometry.
Detection of apoptosis by TUNEL assay
Apoptosis was determined using the TUNEL assay for
the identification of double-stranded DNA breaks
according to the manufacturer’s instructions. Briefly, tis-
sue paraffin sections were washed three times with PBS
for 10 minutes each time, dehydrated for 2 minutes in
absolute ethanol and then treated with permeabilization
solution (1% Triton X-100 in 1% sodium citrate) for 15
minutes at room temperature. Strand breaks were labeled
with fluoresceinated dUTP and visualized following reac-
tion with antifluorescein antibody conjugated with horse-
radish peroxidase and diaminobenzidine substrate. All
slides were counter-stained using hematoxylin.
Mitochondrial membrane potential assay
Treated cells were washed twice and incubated in com-
plete medium containing 10 μg fluorescent lipophilic
cationic JC-1 dye for 30 minutes at 37°C in the dark.
Stained cells were harvested, washed, resuspended, and
subjected to immediate analysis by a laser confocal scan-
ning microscopy. JC-1 was selectively accumulated in
intact mitochondria and formed multimer J-aggregates
that fluoresced red (590 nm) at a high membrane poten-
tial. Monomeric JC-1 fluoresced green (527 nm) at a low
membrane potential. The different colors for fluores-
cence of JC-1 thus represented different mitochondrial
membrane potentials.
Western blot analysis
Treated cells were lysed in cytosol-extracting buffer (10
mM HEPES, 10 mM KCl, 0.1 mM ethylenediamine tet-
racetic acid, 1.5 mM MgCl2, 0.2% NP40, 1 mM dithio-
threitol, and 0.5 mM phenylmethylsulfonyl fluoride) for
2 minutes, and supernatants (cytosolic fraction) were
collected by centrifugation at 12,000 rpm for 5 minutes
at 4°C [19]. Cytosolic extracts were resolved in a 12.5%
polyacrylamide gel and transferred, and the blot was
hybridized with cytochrome C antibody. The signal was
developed using an ECL kit and the relative photo-
graphic density was quantified by LAS-3000 Image
Reader (Fujifilm, Tokyo, Japan).
Plasmids, oligonucleotides and transfections
To construct plasmids expressing miR-34a and miR-21,
the genomic fragment containing miR-34a and miR-21
precursor was amplified from MDA-MB-453 cells and
cloned into the pcDNA6.2-GW/EmGFP vector. The
PCR primers are as follows: miR-34a, forward 5’-
TTTAAGCTTATGCGCCCTGCC-3’ and reverse 5’-
TTTCTCGAGAGAGCTTCCGAAGTCCTGG-3’; and
miR-21, forward 5’-GAATTCCGATCTTAACAGGCCA-
GAAATGC-3’ and reverse 5’-AGATCTCCACCAGA-
CAGAAGGACCAGAGT-3’. The clones were confirmed
by restriction analysis and DNA sequencing of both
strands (Invitrogen, Shanghai, China). Anti-miR-34a oli-
gonucleotides (5’-ACAACCAGCTAAGACACTGCC-3’)
were from Exiqon (Vedbaek, Denmark). 2’-O-methyl-
anti-miR-21 (5’-UCAUACAGCUAGAUAACCAAAGA-
3’) was chemically synthesized by Genechem (Shanghai,
China). Cells were transfected using Lipofectamine 2000
in Opti-Mem (Invitrogen, Carlsbad, CA, USA), accord-
ing to the manufacturer’s protocol. The medium was
replaced 8 hours later and cells were collected for the
next experiments 48 hours post-transfection. The final
concentrations of oligonucleotides were 100 nM.
Quantitative RT-PCR analysis of miR-34a and miR-21
expression
Total RNA was extracted using Trizol reagent. For detec-
tion of miR-34a and miR-21 expression, stem-loop RT-
PCR was performed as previously described [20,21]. Quan-
titative PCR was carried out using a BioEasy SYBR green I
real-time PCR kit (Bioer, Hangzhou, China) according to
the manufacturer’s protocol. Relative expression was eval-
uated by comparative computed tomography method and
was normalized to the expression of U6 small RNA. The
primers for miR-34a are: stem-loop RT primer 5’-
GTCGTATCCAGTGCAGGGTCCGAGGTATTCG-
CACTGGATACGACAACAAC-3’, forward 5’-CGGTAT-
CATTTGGCAGTGTCT-3’ and reverse 5’-
GTGCAGGGTCCGAGGT-3’. The primers for miR-21
are: RT primer 5’-GTCGTATCCAGTGCAGGGTCC-
GAGGTATTCGCACTGGATACGACTCAACA-3’, for-
ward 5’-GCCCGCTAGCTTATCAGACTGATG-3’ and
reverse 5’-GTGCAGGGTCCGAGGT-3’. The primers for
U6 are: RT primer 5’-GTCGTATCCAGTGCAGGGTCC-
GAGGTATTCGCACTGGATACGACAAAAATATG-3’,
forward 5’-GCGCGTCGTGAAGCGTTC-3’ and reverse
5’-GTGCAGGGTCCGAGGT-3’. All quantitative RT-
PCRs were performed in triplicate.
Statistical analysis
Statistical analyses were performed using the SPSS 11.0
package (SPSS Inc., Chicago, IL, USA). Results are pre-
sented as the mean ± standard deviation, for at least
three independent experiments. Tumor incidences were
Hui et al. Breast Cancer Research 2012, 14:R80
http://breast-cancer-research.com/content/14/3/R80
Page 4 of 11
compared using the chi-squared test. Other data were
analyzed by one-way analysis of variance followed by
Tukey’s test for multiple comparisons. Significance of
difference was set at P < 0.05.
Results
Bioavailability of 3,6-dihydroxyflavone in rats
After administration of 3,6-DHF (20 mg/kg/day), the
plasma and urine of the rats were collected and analyzed
by HPLC (Figure 1). The concentration of 3,6-DHF in
the plasma within 2 hours after ingestion was 2.5 ± 0.4
μg/ml, and the average concentration of 3,6-DHF in the
urine within 24 hours was 21.7 ± 3.8 μg/ml.
Chemopreventive effects of 3,6-dihydroxyflavone against
breast carcinogenesis in rats
Three end points of the carcinogenic response in MNU-
treated groups were measured: tumor incidence
(number of tumor-bearing rats divided by the total
number of rats in a group), tumor latency (time to
detection of a palpable mammary tumor), and tumor
multiplicity (average number of tumors per rat). As
shown in Table 1, the tumor incidence and multiplicity
in the high-dosage group were significantly lower than
in the control group. The cancer incidence was
decreased by 35.7%, indicating that oral administration
of 3,6-DHF (20 mg/kg/day) can effectively suppress
MUN-induced mammal carcinogenesis. No evidence of
adverse effects was observed in rats administered with
3,6-DHF orally and they grew at the same rate as the
controls.
3,6-Dihydroxyflavone inhibits the growth of breast cancer
cells in vivo
We evaluated the anti-tumor activity of 3,6-DHF in
athymic mice xenografted with human tumor models.
Figure 1 Spectrum of graphs for HPLC analysis. After administration of 3,6-dihydroxyflavone (3,6-DHF) (20 mg/kg/day), plasma within 2 hours
and urine within 24 hours of the rats were collected and analyzed by HPLC (n = 6). Arrows indicate peaks of 3,6-DHF.
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The tumor volume in 3,6-DHF-treated mice was smaller
than that in the control mice on the same measurement
day (Figure 2). At the end of the 28-day treatment, the
tumor weight in 3,6-DHF-treated mice was less than
that in the control mice, and the T/C values for 10 and
20 mg/kg/day 3,6-DHF treatment groups were 57.2%
and 36.4%, respectively. These results indicate that 3,6-
DHF could inhibit the growth of breast cancer cells in
vivo.
Expression of miR-34a and miR-21 in breast
carcinogenesis and the influence of 3,6-dihydroxyflavone
We detected the expressions of miR-21 and miR-34a in
rat breast tissue at 0, 4, 8 and 18 weeks after MNU
injection, respectively. The results revealed the global
upregulation of miR-21 expression and downregulation
of miR-34a expression at all time points in breast carci-
nogenesis. As shown in Figure 3, 3,6-DHF administra-
tion could significantly inhibit the upregulation of miR-
21 and effectively increase the expression of miR-34a.
3,6-Dihydroxyflavone induced apoptosis of breast cancer
cell in vitro and in vivo
Apoptosis analysis using flow cytometry showed that
3,6-DHF induced apoptosis of breast cancer cell in a
dose-dependent manner (Figure 4A). We also detected
the effect of 3,6-HDF on cell apoptosis in human vascu-
lar endothelial cell line EA.hy926, a normal cell line. As
shown in Figure 4A, no significant effects were
observed. To characterize the upstream factors involved
in 3,6-HDF-induced apoptosis in breast cancer cells, the
mitochondrial permeability of cells was measured by JC-
1 staining-based flow cytometry. As shown in Figure 4B,
the significant decrease in the ratio of JC-1 red/green
fluorescence indicated a loss of mitochondrial mem-
brane potential. The disruption of mitochondrial mem-
brane was known to result in the release of cytochrome
C into the cytosol, which was detected by western blot
analysis (Figure 4C). These results revealed that the
treatment of breast cancer cells with 3,6-DHF induced
apoptosis by decreasing mitochondrial membrane poten-
tial and releasing cytochrome C in vitro.
We also detected the apoptosis of xenografted tumor
and MNU-induced breast tumor by TUNEL assay. As
shown in Figure 4D, E, consistent with the results in
vitro, the immunohistochemical analysis of sections
from tumor subjects showed that 3,6-HDF induced
apoptosis of breast cancer cells in vivo.
miR-34a and miR-21 play roles in 3,6-dihydroxyflavone-
induced apoptosis in breast cancer cells
Detections using quantitative RT-PCR indicated 3,6-
DHF treatment significantly upregulated the miR-34a
level and decreased miR-21 expression of breast cancer
cells in vitro and in vivo (Figure 5B, C). To explore the
effects of miR-34a and miR-21 in the anticancer activ-
ities of 3,6-DHF, we constructed plasmids expressing
miR-34a or miR-21, respectively. Transient transfection
of these plasmids led to substantial production of
mature miR-34a or miR-21 in breast cancer cells (Figure
5B, C). In transfected breast cancer cells, overexpressed
miR-34a markedly promoted 3,6-DHF-induced cytotoxi-
city and apoptosis. Meanwhile, miR-21 overproduction
exerted converse affects, compromising the anticancer
effects of the flavonoid (Figure 5D, E). Furthermore, a
locked nucleic acid oligonucleotide complementary to
the miR-34a sequence (anti-miR-34a) served to block
miR-34a function. Inhibition of miR-34a in cancer cells
led to a marked decrease in 3,6-DHF-induced cytotoxi-
city and apoptosis. In contrary, inhibition of miR-21 by
2’-O-methyl-anti-miR-21 led to a significant increase in
3,6-DHF-induced apoptosis.
Discussion
Natural compounds and synthetic chemicals that have
been shown to inhibit or reverse carcinogenesis have
been increasingly adopted in the field of chemopreven-
tion [22,23]. Cancer-preventive phytochemicals have
been shown to suppress or block cancer progression by
a variety of mechanisms. Development of anticancer
agents from flavonoids and other natural products has
currently become a very hot topic.
Our previous study identified a flavonoid compound
3,6-DHF as a promising anticancer agent with a very
Table 1 Effect of 3,6-dihydroxyflavone on cancer endpoints and body weight
Group Total number of
rats










No treatment 8 0 0 - - 291.3 ± 5.2
MNU only 14 13 92.8 2.6 ± 0.6 74.4 ± 7.1 281.7 ± 4.8
MNU + 10 mg/kg
3,6-DHF
14 9 64.3 2.2 ± 0.3 80.8 ± 7.8 275.5 ± 5.8
MNU + 20 mg/kg
3,6-DHF
14 8* 57.1* 1.9 ± 0.4* 87.5 ± 5.1** 278.7 ± 5.1
Data presented as mean ± standard deviation. *P < 0.05, **P < 0.01 compared with the 1-methyl-1-nitrosourea (MNU)-only treatment group. Tumor incidence in
the MNU + 20 mg/kg 3,6-dihydroxyflavone (3,6-DHF) treatment group was significantly lower than that in the MNU-only treatment group, indicating that oral
administration of 3,6-DHF (20 mg/kg/day) can effectively suppress MUN-induced mammal carcinogenesis.
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Figure 2 3,6-Dihydroxyflavone significantly inhibited the growth of MDA-MB-231 cells in athymic mice. The weight of the mice and the
tumor volume were recorded every 4 days until animal sacrifice at day 28. (A) Tumor volume in each group. (B) Tumor weight at the end of
the 28-day treatment. (C) Photograph of tumors at the end of the treatment. Data presented as mean ± standard deviation (n = 6). **P < 0.01
compared with control.
Figure 3 Expressions of miR-21 and miR-34a in breast carcinogenesis and the influence of 3,6-dihydroxyflavone. Expression of
microRNA-21 (miR-21) and microRNA-34a (miR-34a) in rat breast tissue was detected by quantitative RT-PCR at 0, 4, 8, 18 weeks after 1-methyl-
1-nitrosourea injection, respectively. Data presented as mean ± standard deviation (n = 3). **P < 0.01 compared with control at each time point.
#P < 0.05, # #P < 0.01 compared with control at 0 weeks.
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strong cytotoxicity against breast cancer cells and a
stronger anticancer activity in vitro than apigenin, genis-
tein, quercetin, luteolin, and so forth [16-18]. In the pre-
sent study, we investigated the anticancer effect of 3,6-
DHF in vivo. The results indicate that oral administra-
tion of 3,6-DHF can effectively suppress MUN-induced
mammary carcinogenesis and inhibit the transplanted
tumor growth of breast cancer cells in vivo. We have so
far demonstrated that 3,6-DHF is an effective chemopre-
ventive and chemotherapeutic agent, having efficient
anticancer activities against breast cancer cells in vitro
and in vivo. Furthermore, we revealed that 3,6-DHF
induced apoptosis of breast cancer cells by decreasing
mitochondrial membrane potential and releasing cyto-
chrome C.
miRNAs are well known to play important roles in
the pathogenesis of human diseases, including malig-
nancy, and may function as both oncogenes and tumor
suppressors - abnormal expression of miRNAs pro-
motes carcinogenesis and cancer progression [24,25].
In this study, we revealed the global upregulation of
miR-21 expression and downregulation of miR-34a
expression at all the three time points after MNU
injection, which could be reversed by 3,6-DHF oral
administration. 3,6-DHF significantly upregulated miR-
34a expression and decreased miR-21 expression,
Figure 4 3,6-Dihydroxyflavone induced apoptosis of breast cancer cells in vitro and in vivo. (A) After being treated with 3,6-
dihydroxyflavone (3,6-DHF) for 24 hours at increasing concentrations (5, 10, and 20 μM), apoptosis of breast cancer MDA-MB-453 cells increased
in a dose-dependent manner. (B) Treatment with 10 μM 3,6-DHF caused the loss of mitochondrial membrane potential in a time-dependent
manner. (C) Treatment with 10 μM 3,6-DHF induced cytochrome C release in a time-dependent manner. (D) Detection of tumor xenograft
apoptosis by TUNEL assay. (E) Detection of 1-methyl-1-nitrosourea-induced tumor apoptosis by TUNEL assay. Stained nuclei dark brown in color
represent apoptotic cells. Arrows indicate apoptotic nuclei. Data presented as mean ± standard deviation (n = 3). *P < 0.05, **P < 0.01 compared
with control. JC-1, 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethyl-imidacarbocyanine iodide.
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inducing apoptosis of breast cancer cells in vitro and
in vivo. Furthermore, overexpression of miR-34a
induced by plasmid transfection or inhibition of miR-
21 by oligonucleotides markedly promoted the pro-
apoptotic effect of 3,6-DHF, while inactivation of miR-
34a or overproduction of miR-21 compromised the
anticancer effects of 3,6-DHF. We hypothesize that the
disbalance of cell apoptosis signaling regulation plays
an important role in breast tumorigenesis. The flavo-
noid suppressed carcinogenesis and induced apoptosis
of breast cancer cells partially through miR-21 and
miR-34a association.
miR-21, a putative oncogene, is most frequently over-
expressed in a variety of malignancies, especially in
breast cancer, and it has been shown to be implicated in
multiple malignancy-related processes including cell
proliferation, apoptosis, invasion, and metastasis [26-28].
miR-34a was demonstrated to be a direct transcriptional
target of p53, and a component of the p53 transcrip-
tional network [29-31]. miR-34a expression is sufficient
to induce apoptosis through p53-dependent mechanisms
[32,33]. Loss of function of the p53 tumor suppressor
protein causes the pathogenesis of a large fraction of
human malignancies [34,35]. Given the importance of
Figure 5 Increasing intracellular miR-34a or silencing miR-21 expression promoted 3,6-dihydroxyflavone-induced breast cancer cell
cytotoxicity and apoptosis. (A) Photomicrographs of transfected cells by fluorescence microscopy. (B) Expression of microRNA-34a (miR-34a) in
each cell and the effect of 3,6-dihydroxyflavone (3,6-DHF). (C) Expression of microRNA-21 (miR-21) in each cell and the effect of 3,6-DHF. (D)
Effect of 3,6-DHF (10 μM) treatment for 24 hours on cell viability. (E) Effect of 3,6-DHF (10 μM) treatment for 24 hours on cell apoptosis. Data
presented as mean ± standard deviation (n = 3). *P < 0.05, **P < 0.01 compared with control in each group. #P < 0.05, ##P < 0.01 compared
with the MDA-MB-453 breast cancer cell (BC) group. TX, tumor xenograft of MDA-MB-231 breast cancer cells; MC, MDA-MB-453 cells transfected
with blank plasmids (mock cells); TC34a, MDA-MB-453 cells transfected with pcDNA6.2-GW/miR-34a; TC21, MDA-MB-453 cells transfected with
pcDNA6.2-GW/miR-21. All transfected cells were collected for the next experiments 48 hours after transfection.
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pro-apoptosis activity of miR-34a and anti-apoptosis
activity of miR-21 in cancer cells, it is interesting to
investigate thoroughly their roles in carcinogenesis and
anticancer effects of flavonoids.
Conclusions
Our study shows that oral administration of 3,6-DHF
effectively suppresses MNU-induced breast carcinogen-
esis and transplanted tumor growth in vivo, indicating
that 3,6-DHF is a potent natural chemopreventive agent.
Furthermore, our study also reveals that miR-34a and
miR-21 play roles in MNU-induced breast carcinogen-
esis and the anticancer mechanism of the flavonoid.
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